Abstract: A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.

Abstract: Sustained release pharmaceutical formulations containing morphine, or a pharmaceutically acceptable salt thereof, as active ingredient, suitable for administration on a once daily basis, are disclosed. In a first aspect, an orally administrable sustained release unit dosage form gives a peak plasma level at 1.0 to 6 hours after administration. In a second aspect, the formulation provides a W.sub.50 for the M-6-G metabolite for morphine of between 4 and 12 hours. A third aspect concerns the pharmaceutical unit dosage form obtained by compressing multiparticulates comprising a pharmaceutically active substance in a matrix of hydrophobic fusible material having a melting point of from 35.degree. to 150.degree. C.

Abstract: A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.

Abstract: A controlled-release pharmaceutical preparation comprising diamorphine, or a pharmaceutically acceptable salt thereof.

Abstract: A vehicle with a hood latch assembly includes a latch and latch catch having relative positions which are maintained as the hood closed position of the hood is adjusted to thereby maintain a substantially constant load on the latch assembly. The assembly may include a latch catch with a latch body having an upper hood engaging surface for engaging the hood and isolating hood vibrations. An upwardly projecting neck of the latch catch includes an enlarged head portion with a latch engaging pin. A latch mount incorporated into the latch catch is utilized for coupling the latch catch to a vehicle body. The latch mount may be slidably mounted to a flange of a mounting bracket which is fixedly mounted to the vehicle body. A stop mounted to the vehicle hood engages the upper surface of the latch catch when the hood is in the hood closed position. The latch includes a latch base, a handle pivoted thereto, and a latch hook having a pivot portion pivoted within a yoke of the handle and a hook.

Abstract: A vehicle having a side-mounted fairing for reducing aerodynamic drag in which a portion of the fairing is easily removable to allow access to vehicle components is disclosed. The removable fairing includes a convolute sheet of substantially rigid material in which planar surfaces are formed for providing steps. Support rails are mounted to an inner surface of the fairing just below the steps to connect the fairing to the vehicle and to support weight placed on the steps. The rails include mortise and tenon connections for connecting the removable fairing portion to a fixed portion of the fairing. In addition, support brackets are fixedly attached to the vehicle and extend outward to provide support for the removable fairing. Fasteners are provided for securing the removable fairing to the vehicle and to the fixed portion of the fairing.

Abstract: A stable pharmaceutical composition with reduced irritancy is provided, the composition comprising an aqueous solution of elemental iodine and at least one organic substance which reacts with iodine, whereby iodine loss is controlled by providing a source of iodate ions in an amount sufficient to provide from 0.01% to 0.04% by weight iodate ions, preferably from 0.02% to 0.03% by weight iodate ions.

Abstract: A controlled release composition including spheroid cores of diltiazem or a pharmaceutically acceptable salt thereof and optionally a spheronizing agent, the cores being coated with a controlled release layer, and a method of manufacturing the same, is disclosed. The spheronizing agent when present is preferably microcrystalline cellulose. Ethylcellulose is a preferred release coating. The controlled release coating preferably contains a plasticizer, a surfactant and a tack-modifier.

Abstract: Slow release pharmaceutical compositions comprising a combination of a higher aliphatic alcohol and a hydrated hydroxy-alkyl cellulose in ratio of from 2:1 to 4:1 parts by weight and comprising from 20 to 40 percent by weight of the composition; the method for making the same, and their inclusion in pharmaceutical dosage forms intended for oral administration, to provide a slow release of a therapeutically active compound during a predetermined period of time of from 5 to 10 hours, after oral ingestion by humans and animals.